Perioperative blood transfusion adversely affects prognosis after nephrectomy for renal cell carcinoma

Abu-Ghanem, Yasmin; Zilberman, Dorit E.; Dotan, Zohar; Kaver, Issac; Ramon, Jacob

doi:10.1016/j.urolonc.2017.09.006

Cited by 24 publications

(22 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Few recent studies by Moschini M. et al . 10,14,15 confirmed these results, also on RC patients (Table 3).…”

Section: Discussionsupporting

confidence: 77%

“…In the entire cohort, PBT was associated with poor outcomes including 5-yr RFS (81% vs. 92% P < 0.01), metastatic free survival (79% vs. 93% P < 0.001), CSS (85% vs 95%; P < 0.001) and OS (73% vs 81%; P < 0.001), respectively 15 . After stratification according to the timing of BT administration (postoperative transfusion vs. intraoperative transfusion), we compared the 3 groups of interest: Intraoperative vs. No BT, postoperative vs. No BT, Intraoperative vs. postoperative BT.…”

Section: Resultsmentioning

confidence: 90%

See 1 more Smart Citation

Intraoperative but not postoperative blood transfusion adversely affect cancer recurrence and survival following nephrectomy for renal cell carcinoma

Abu-Ghanem

Dotan

Zilberman

et al. 2019

Sci Rep

Self Cite

View full text Add to dashboard Cite

The association between perioperative blood transfusion (PBT) with adverse oncological outcomes have been previously reported in multiple malignancies including RCC. Nevertheless, the importance of transfusion timing is still unclear. The primary purpose of this study is to appraise whether the receipt of intraoperative blood transfusion (BT) differ from postoperative BT in regards to cancer outcomes in renal cell carcinoma (RCC) patients treated with nephrectomy. Data on 1168 patients with RCC, who underwent radical or partial nephrectomy as primary therapy between 1988–2013 were analyzed. PBT was defined as transfusion of allogeneic red blood cells (RBC) during surgery or the postsurgical period. Survival was analyzed and compared using the Kaplan–Meier method with the log-rank test. Of 1168 patients, 198 patients (16.9%) received a PBT. Including 117 intraoperative BT and 81 postoperative BT. Only 21 (10.6%) patients required both intraoperative and postoperative BT. On multivariate analyses, receipt of PBT was associated with significantly worse local disease recurrence (HR: 2.4; P = 0.017), metastatic progression (HR: 2.7; P = 0.005), cancer-specific mortality (HR: 3.5; P = 0.002) and all-cause mortality (HR: 2.1; P = 0.005). Nevertheless, postoperative BT was not independently associated with increased risk of local recurrence (p = 0.1), metastatic progression (P = 0.16) or kidney cancer death (P = 0.63), yet did significantly increase the risk of overall mortality (HR: 2.6; P = 0.004). In the current study, intraoperative transfusion of allogeneic RBC is associated with increased risks of cancer recurrence and mortality following nephrectomy.

show abstract

“…Few recent studies by Moschini M. et al . 10,14,15 confirmed these results, also on RC patients (Table 3).…”

Section: Discussionsupporting

confidence: 77%

Section: Resultsmentioning

confidence: 90%

Intraoperative but not postoperative blood transfusion adversely affect cancer recurrence and survival following nephrectomy for renal cell carcinoma

Abu-Ghanem

Dotan

Zilberman

et al. 2019

Sci Rep

Self Cite

View full text Add to dashboard Cite

show abstract

“…47 Abu-Ghanem and colleagues mentioned that the main effect on prognosis appears only after a follow up of at least 4–5 years. 47…”

Section: Methodsmentioning

confidence: 99%

“…Notably, in response to the last issue, Abu-Ghanem and colleagues conducted a multivariate analysis to include the additional clinicopathological variables and discovered that PBT remained significantly associated with increased risks of disease-free survival [hazard ratio (HR) = 2.1, p = 0.02], metastatic progression (HR = 2.4, p = 0.007), CSS (HR = 2.5, p = 0.02) and OS (HR = 2.2, p = 0.001). 47 Abu-Ghanem and colleagues mentioned that the main effect on prognosis appears only after a follow up of at least 4-5 years. 47 As opposed to these studies, a multicenter study by Park and colleagues found no association between PBT and prognosis in patients with RCC, following propensity score matching analysis.…”

Section: Bladder Cancermentioning

confidence: 99%

“…47 Abu-Ghanem and colleagues mentioned that the main effect on prognosis appears only after a follow up of at least 4-5 years. 47 As opposed to these studies, a multicenter study by Park and colleagues found no association between PBT and prognosis in patients with RCC, following propensity score matching analysis. 14 Recently, Arcaniolo and colleagues 48 addressed this debate by conducting a systematic review and pooled However, despite the significant decrease in PBT rate following RP, the risk of bleeding remains a major concern, mainly since intraoperative bleeding can have an effect on perioperative morbidity, primarily, transfusion requirements.…”

Section: Bladder Cancermentioning

confidence: 99%

See 1 more Smart Citation

Impact of perioperative blood transfusions on clinical outcomes in patients undergoing surgery for major urologic malignancies

Abu-Ghanem

Ramon

2019

Therapeutic Advances in Urology

Self Cite

View full text Add to dashboard Cite

The association between allogeneic perioperative blood transfusion (PBT) and decreased survival among patients undergoing various oncological surgeries has been established in various malignant diseases, including colorectal, thoracic and hepatocellular cancer. However, when focusing on urologic tumors, the significance of PBT and its adverse effect remains debatable, mainly due to inconsistency between studies. Nevertheless, the rate of PBT remains high and may reach up to 62% in patients undergoing major urologic surgeries. Hence, the relatively high rate of PBT among related operations, along with the increasing prevalence of several urologic tumors, give this topic great significance in clinical practice. Indeed, recent retrospective studies, followed by systematic reviews in both prostate and bladder cancer surgery have supported the association that has been demonstrated in several malignancies, while other major urologic malignancies, including renal cell carcinoma and upper tract urothelial carcinoma, have also been addressed retrospectively. It is only a matter of time before the data will be sufficient for qualitative systematic review/qualitative evidence synthesis. In the current study, we performed a literature review to define the association between PBT and the oncological outcomes in patients who undergo surgery for major urologic malignancies. We believe that the current review of the literature will increase awareness of the importance and relevance of this issue, as well as highlight the need for evidence-based standards for blood transfusion as well as more controlled transfusion thresholds.

show abstract

The Effects of Perioperative Transfusion of Allogenic Blood Products of Cancer Recurrence

Jiang

Karri

Mathias

et al. 2021

Essentials of Blood Product Management in Anesthesia Practice

View full text Add to dashboard Cite

Perioperative blood transfusion adversely affects prognosis after nephrectomy for renal cell carcinoma

Cited by 24 publications

References 21 publications

Intraoperative but not postoperative blood transfusion adversely affect cancer recurrence and survival following nephrectomy for renal cell carcinoma

Intraoperative but not postoperative blood transfusion adversely affect cancer recurrence and survival following nephrectomy for renal cell carcinoma

Impact of perioperative blood transfusions on clinical outcomes in patients undergoing surgery for major urologic malignancies

The Effects of Perioperative Transfusion of Allogenic Blood Products of Cancer Recurrence

Contact Info

Product

Resources

About